source
- New evidence links gene‑therapy viral vectors to tumor formation in pediatric patientsFor years, scientists have debated whether the viral vectors used in gene therapy could cause cancer. Recent case reports now provide strong evidence that such a risk is real. The reports involve…
- Argenx to acquire Unnatural Products' macrocyclic peptide platform for $550 million upfrontArgenx announced that it will acquire the California-based protein specialist Unnatural Products, paying $550 million upfront for its macrocyclic peptide platform. The deal could rise to more than…